Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$1.53 - $2.89 $49,266 - $93,058
-32,200 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$2.67 - $4.68 $6,052 - $10,609
-2,267 Reduced 6.58%
32,200 $86,000
Q4 2021

Feb 11, 2022

SELL
$3.87 - $7.39 $3,989 - $7,619
-1,031 Reduced 2.9%
34,467 $149,000
Q3 2021

Nov 12, 2021

SELL
$4.32 - $6.43 $3,646 - $5,426
-844 Reduced 2.32%
35,498 $181,000
Q2 2021

Aug 13, 2021

BUY
$6.33 - $9.91 $2,804 - $4,390
443 Added 1.23%
36,342 $230,000
Q1 2021

May 07, 2021

BUY
$6.6 - $9.0 $63,723 - $86,895
9,655 Added 36.79%
35,899 $277,000
Q4 2020

Feb 12, 2021

SELL
$6.47 - $7.9 $4,865 - $5,940
-752 Reduced 2.79%
26,244 $172,000
Q3 2020

Nov 04, 2020

SELL
$6.55 - $8.83 $4,028 - $5,430
-615 Reduced 2.23%
26,996 $180,000
Q2 2020

Aug 12, 2020

BUY
$7.4 - $14.64 $7,081 - $14,010
957 Added 3.59%
27,611 $230,000
Q1 2020

May 04, 2020

SELL
$3.61 - $8.6 $5,563 - $13,252
-1,541 Reduced 5.47%
26,654 $204,000
Q4 2019

Feb 05, 2020

SELL
$5.17 - $8.91 $1,230 - $2,120
-238 Reduced 0.84%
28,195 $234,000
Q3 2019

Nov 08, 2019

SELL
$7.38 - $12.25 $1,461 - $2,425
-198 Reduced 0.69%
28,433 $210,000
Q2 2019

Aug 13, 2019

BUY
$9.35 - $11.41 $2,318 - $2,829
248 Added 0.87%
28,631 $321,000
Q1 2019

May 06, 2019

SELL
$9.5 - $19.16 $8,740 - $17,627
-920 Reduced 3.14%
28,383 $305,000
Q4 2018

Feb 13, 2019

SELL
$12.69 - $18.61 $2,867 - $4,205
-226 Reduced 0.77%
29,303 $442,000
Q3 2018

Nov 09, 2018

BUY
$18.04 - $26.41 $79,502 - $116,388
4,407 Added 17.54%
29,529 $546,000
Q2 2018

Aug 08, 2018

BUY
$21.38 - $29.68 $140,060 - $194,433
6,551 Added 35.28%
25,122 $574,000
Q1 2018

May 07, 2018

SELL
$21.76 - $34.22 $21,716 - $34,151
-998 Reduced 5.1%
18,571 $528,000
Q4 2017

Feb 09, 2018

BUY
$19.0 - $23.09 $1,748 - $2,124
92 Added 0.47%
19,569 $413,000
Q3 2017

Nov 09, 2017

BUY
$13.53 - $18.17 $263,523 - $353,897
19,477
19,477 $354,000

Others Institutions Holding CTMX

About CytomX Therapeutics, Inc.


  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $66M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.